ABSTRACT
Introduction
Interferon-gamma (IFNγ) is synthesized by cells of the immune system (natural killer cells, CD4 T h 1 cells and CD8 cytotoxic lymphocytes) in response to mitogenic and antigenic stimuli (1, 39) . It is endowed with multiple biological effects through orchestration of a remarkable spectrum of distinct cellular programs. Hundreds of genes are regulated by this cytokine, and the complexity of the signalling responses is accentuated by cell-specific transcriptional programs and several IFNγ regulated genes that are themselves components of transcription factors (5, 15, 30) . the major function that can be attributed to IFNγ is regulation of the innate and adaptive immunity. The properties of IFNγ include also: stimulation of antiviral and bactericidal activity; increase of antigen presentation; activation and increase of lysosome activity in macrophages; suppression of T h 2 cell activity; promotion of adhesion and binding of leukocytes; promotion of T h 1 differentiation; promotion of NK cell activity and effects on cell proliferation and apoptosis (35) . Microarray analysis reveals a wide range of transcripts that are regulated by IFNγ, including many with immunomodulatory functions as well as a variety of genes whose functional significance remains obscure. In general, IFNγ induces a proinflammatory phenotype through the induction and upregulation of membrane receptors and secretion products (26) . Related to its multiple biological activities, IFNγ is a prospective substance for pharmacy (35) .
Human interferon-gamma (hIFNγ) consists of 143 amino acids, 28 of which are Lys and Arg. Its single polypeptide chain is organized in six α-helices (no β-sheets) comprising 62 % of the whole molecule, which are linked by unstructured regions (12) . The active form of hIFNγ is a stable non-covalent homodimer interacting with a hIFNγ specific receptor (10), thus activating the JAK/STAT pathway (20) . The natural (immune) hIFNγ carries two N-glycosylation sites (Asn25 and Asn97), which are exposed on the surface of the homodimer (29) . Glycosylation is dispensable for biological activity, but it is important for the solubility and protease resistance of hIFNγ. The glycan residues, especially those at Asn25, play an important role in protease resistance to granulocyte proteases, purified elastase, cathepsin G and plasmin (29) .
Because it is secreted in minute concentrations in human blood, hIFNγ is produced as a recombinant protein. The hIFNγ gene was successfully expressed in E. coli almost three decades ago (17, 33, 34) and this expression was improved in the following years (3, 8, 18, 24) . In spite of the high biological activity of the bacterial product, bacterial expression has demonstrated the following disadvantages: i) hIFNγ aggregates in E. coli cells in the form of insoluble protein particles (inclusion bodies) in which the protein is partly or completely denatured; the latter complicates its purification because a denaturation/renaturation step is required (27, 31) ; ii) bacterial hIFNγ is non-glycosylated, tends to aggregate in water solutions and has shorter half-life in the bloodstream; iii) bacterial hIFNγ is glycated (i.e. non-enzymatically glycosylated) and due to this it is modified by advanced glycation endproducts (AGEs). The AGEs formation itself causes covalent dimerization and polymerization, non-enzymatic proteolysis, decrease in biological activity and increase in immunogenicity (22, 23) . Both glycation and incomplete refolding contribute
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Peter leister 1, 3 , Milena Tileva 2 , elena Krachmarova 2 and Genoveva Nacheva significantly to the instability of hIFNγ in water solutions. Attempting to overcome these shortcomings, the hIFNγ gene has also been expressed in yeast (11) , Chinese hamster ovary (CHO) cells (9, 14, 32) , chloroplasts (36) , transgenic plants (7) and, recently, in the milk of transgenic mice (2) . Unfortunately, none of these expression systems gave satisfactory results in terms of yield, physical-chemical stability, accuracy of glycosylation, biological activity, etc., which justified the search for new approaches for hIFNγ gene expression. In this study we present our results on expression of the hIFNγ gene, applying transient transfection of human suspension culture cells.
Materials and Methods
A recombinant hIFNγ gene was cloned into the expression vector pJW003 (CEVEC, Cologne). Plasmid DNA was isolated using endotoxin-free plasmid preparation kit (Qiagen, Hilden) and used for transfection of CAP-T (CEVEC, Cologne) and HEKF (Invitrogen, Darmstadt) cells. Cells were grown in suspension using shaking flasks on a shaker (120 rpm, 5 cm amplitude) as well as in a bioreactor at 37 °C and 5 % CO 2 . Transfection was carried out by jetPEI transfection reagent (from Polyplus) at a ratio of DNA:PEI = 2:1 and 2.5 pg DNA per cell in FreeStyle and PEM media (Invitrogen) at a cell density of 2.5×10
6 cells/mL. Growth media were supplemented with valproic acid (VPA, up to 4 mmol/L), glucose (3 mg/mL) and peptone (4 mg/mL). Normally, transient expression cell cultures were maintained for 10 to 14 days and supernatants were harvested when the cell viability decreased below 50 %. During that time the cell density usually increased up to 2×10 7 cells/ml.
Cell viability was assessed by the ability of cells to exclude Trypan blue (0.2 %, w/v, final concentration) (28), using a Neubauer chamber.
Biological activity of the expressed in the supernatant protein was measured by hIFNγ antiproliferative activity on WISH cells following a modified kynurenine bioassay (6) .
Concentration/yield of hIFNγ was measured by ELISA using the Ready-Set-Go! kit for human interferon gamma (NatuTec), following the manufacturer's instructions.
Results and Discussion
Aiming to obtain recombinant hIFNγ with a molecular structure as close as possible to that of the native (lymphocyte) hIFNγ, we employed a transient gene expression approach using two already established human cell lines: CAP-T and HEKF. CAP-T represents immortalized human amniotic cells, originally developed by CEVEC, Cologne (16) . HEKF are human embryonic kidney cells (HEK293) adapted to grow in suspension (Invitrogen, Darmstadt). Both cell lines are commonly used by InVivo Biotech Services GmbH (Berlin, Germany) for industrial expression of human proteins, using transient transfection, approaching yields of about 30 mg/L. Initially, the experiments were carried out in minimal volumes (8 mL) of CAP-T and HEKF cell cultures to obtain samples for analytical purposes. In contrast to other transient expression experiments and to the control cells (both nontransfected but treated with transfection reagent and transfected with "empty vector"), in the case of hIFNγ both cell lines did not show the awaited proliferation levels after the transfection step. In addition, the cell viability decreased much faster and reached the critical level of 50 % after five days only (Fig. 1) . Subsequently, the cell density did not exceed 0.7×10 5 cells/ml, compared to 2×10 5 cells/mL for the control cells, and sharply decreased after four days of cultivation (Fig. 2) . The yield of hIFNγ secreted in the supernatant from both transfected cell lines was low, too. It did not exceed 0.3 mg/L to 1.5 mg/L ( Table 1) . In order to improve the yield of hIFNγ, further experiments were carried out with a larger cultivation volume (70 mL) in shaking flasks allowing more efficient agitation. In addition, 4 mmol/L VPA (for inhibition of histone deacetylases) was added and three days later the glucose and peptone concentration were adjusted to 3 mg/mL and 4 mg/mL, respectively.
These results, however, were again disappointing. Although everything possible to our knowledge was done to improve the cell comfort and expression efficiency, both cell cultures demonstrated poor growth and viability. The yield of hIFNγ did not exceed 5.83 mg/L ( Table 1) . Despite the low yield, its activity was 1.93×10
7 IU/mg (corresponding to the biological activities of both natural and bacterial hIFNγ).
Observing cell behaviour, we concluded that both CAP-T and HEKF cells died most probably by apoptosis. It is known that hIFNγ mediates growth arrest in most cell types (19) . Normally, it induces proliferation of the Th1 lymphocytes but can also induce apoptosis in these cells through the TCR engagement (21) . This difference is attributed to the signal strength and is explained by the different levels of expression of the hIFNγ receptor IFNgR2 (25) . Another factor affecting hIFNγ-responsiveness may be the level of STAT1. Although STAT1 is ubiquitously expressed, the absolute expression levels can vary substantially between cell types and this may interfere with the cellular responses to hIFNγ (13, 37) . hIFNγ may induce cell cycle arrest also through a STAT1-independent mechanism. Thus, exposure of macrophages to hIFNγ causes an arrest at the G1/S phase of the cell cycle (4, 38) .
Conclusions
Based on the results obtained in this study, we conclude that both (CAP-T and HEKF) human cell lines are not appropriate for preparative production of hIFNγ by transient gene expression. We are willing to report these "negative" results in order to prevent others from wasting time and efforts in using the popular CAP-T and HEKF (and maybe other established human cell lines) for hIFNγ transient gene expression.
